Navigation Links
ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
Date:12/16/2009

information, please refer to www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implementation of ChemoCentryx's business model, strategic plans for its business, product candidates and technology, (vi) ChemoCentryx's ability to maintain and establish collaborations or obtain additional government grant funding, (vii) ChemoCentryx's estimates of its expenses, future revenues, capital requirements and its needs for additional financing, (vii
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
2. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
6. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
7. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
8. Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients
9. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
10. Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
11. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015 Boston Scientific Corporation (NYSE: BSX ... th Annual Healthcare Conference on May 6 in ... executive vice president and chief financial officer, and Susie ... 35-minute question and answer session regarding the company with the ... live webcast of the presentation and question and answer session ...
(Date:4/24/2015)... EAST HANOVER, N.J. , April 24, 2015  Novartis ... diversity for the second year in a row on the ... the results of its 2015 Top 50 Companies for Diversity ... New York, NY . NPC also ranked second on ... on the Top 10 Companies for Employee Resource Groups list. ...
(Date:4/24/2015)... /CNW/ - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the ... medical marijuana products and a licensed producer ("LP") to ... ( Canada ) ("MMPR"), is pleased to ... has closed the transaction announced on March 11, 2015 ... "Escrow Transfer") a total of 20,156,790 common shares of ...
Breaking Medicine Technology:Boston Scientific To Participate In The Deutsche Bank 40th Annual Healthcare Conference 2Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 2Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 3Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 4T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3
... R.I., Feb. 18, 2011 CVS Caremark (NYSE: ... Management Institute (PBMI) awarded the company and its PBM ... Rx Benefit Innovation Award.  The award recognizes the Pharmacy ... manage costs, improve medication adherence and close gaps in ...
... Holdings, Inc. (NYSE: ZMH ; SIX: ZMH), a ... clearance for the TM-S Trabecular Metal™ Cervical Interbody ... interbody device incorporating porous metal technology, and the first Zimmer ... in the United States. The TM-S system is ...
Cached Medicine Technology:CVS Caremark Awarded Pharmacy Benefit Management Institute Rx Benefit Innovation Award for Pharmacy Advisor Program 2CVS Caremark Awarded Pharmacy Benefit Management Institute Rx Benefit Innovation Award for Pharmacy Advisor Program 3Zimmer Spine Introduces Industry's First Porous Metal Cervical Interbody Device 2Zimmer Spine Introduces Industry's First Porous Metal Cervical Interbody Device 3
(Date:4/25/2015)... For thirteen years, the Twin Cities DI ... event in the nation! This year, on May 5th, 2015, ... to take DI Day on the road by supporting the ... ChFC, RHU, DIA, CLTC, Chief Executive Officer at Secura Consultants ... the change by stating, "The first Twin Cities DI Day ...
(Date:4/24/2015)... California (PRWEB) April 24, 2015 Ryadon ... a wide range of capabilities and services to complement ... , Ryadon's Quantity Discount Program will be offered on ... follows: , Order 4-19: Receive 10% discount - Order ... by Using the Drawer Slides Products, ...
(Date:4/24/2015)... On February 21st, 2015, Per Wickstrom had the ... contributor Karen Salkin at Durkin Entertainment’s EcoLuxe Lounge, sponsored ... of which Wickstrom is the founder. Making appearances at ... EcoLuxe Lounge is a gathering of some of the ... and services. Among the many roles that she has ...
(Date:4/24/2015)... Integrative Therapeutics has introduced two new supplements focused ... A unique combination of herbs and nutrients, including ... apart from other antioxidant supplements. This formula relies ... versus the use of single or sequential compounds ... Alpha-Glycosyl Isoquercitrin, and Coenzyme Q10 with Setria® Glutathione. ...
(Date:4/24/2015)... National Access Cannabis (NAC), Canada’s provider ... cannabis, is taking a leadership role in ensuring Canadian ... NAC is the first to back mdBriefCase Group Inc.'s ... will be providing 300 healthcare professionals with free access ... Canadians gain safe and responsible access to medical cannabis ...
Breaking Medicine News(10 mins):Health News:Secura Consultants Takes DI Day On The Road 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3Health News:Karen Salkin Talks with Per Wickstrom at the 2015 EcoLuxe Lounge and the "Salute to the Oscars" Celebration 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 3Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 4Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2
... SOMERSET, N.J., Nov. 9 inVentiv Health Inc.,(Nasdaq: ... a new Client Development,and Integration team. The team will ... Chief Client Development Officer. The Client Development and ... segments to identify new opportunities to,serve both new and ...
... Interferon does not slow or halt the progression of ... who havent responded to previous attempts to eradicate the ... University School of Medicine participated has found. , Patients ... experience a significant decrease in viral levels and liver ...
... and techniques of soft condensed matter physics, a research team ... of attractions between proteins keeps the lens of the eye ... can cause proteins to aggregate and de-mix. This leads to ... could shed light on other protein aggregation diseases (such as ...
... after stopping the drug, researchers say , , FRIDAY, Nov. ... at a slightly increased risk for developing cervical cancer, ... very small risk disappears, a new British study suggests. ... women to continue getting screened for cervical cancer, experts ...
... 24 and Taclonex; Company ... financial guidance, ST. DAVID,S, Bermuda, Nov. 9 Warner Chilcott,Limited ... ended,September 30, 2007. Revenue in the quarter ended September 30, 2007 ... The,primary drivers of the increase in revenue were the net sales ...
... Global Commercialization, Program for Once-Daily Tramadol and Completion of Enrolment ... ... QC, Nov. 9 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) ... ended September 30, 2007. All figures are in Canadian dollars ...
Cached Medicine News:Health News:inVentiv Health Creates Client Development and Integration Team 2Health News:inVentiv Health Creates Client Development and Integration Team 3Health News:Interferon does not slow or stop hepatitis C from worsening, study finds 2Health News:Physics provides new insights on cataract formation 2Health News:Pill Poses Little Cervical Cancer Risk 2Health News:Pill Poses Little Cervical Cancer Risk 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 10
... is a monomeric protein produced and stored ... GH is released from the pituitary into ... the regulatory control of hypothalamic somatostatin (SS) ... and frequency of GH release appears to ...
... (IGF-I or somatomedin C) is a 7.6 kDa ... as a potent mitogen of cellular proliferation, exerting ... In the circulation, IGF-I is bound to IGF-binding ... of IGF-I by modulating the interaction of IGF-I ...
... somatomedin C) is a 7.6 kDa peptide produced ... potent mitogen of cellular proliferation, exerting its actions ... circulation, IGF-I is bound to IGF-binding proteins (IGFBPs), ... by modulating the interaction of IGF-I with the ...
... 5a-Dihydrotestosterone (DHT) is a potent naturally ... the action of cholestenone 5a-reductase [1]. ... highest in certain peripheral tissues, including ... are localized intra-cellularly in apparent association ...
Medicine Products: